Search

Somatic symptom and related disorders (SSRD) and functional gastrointestinal disorders (FGID) are common causes of morbidity in children and adults. They are associated with impaired functioning in multiple domains and increasing health care utilization and costs. Their complex nature with medical and psychiatric comorbidities, diverse symptomatology, and often waxing and waning course can make them difficult to study and treat. However, there is some literature in this area regarding pharmacologic and behavioral treatment approaches. This review aims to examine the existing evidence for pharmacological treatments of SSRD and FGID. Several categories of psychotropic medications have been found to be efficacious in many of these disorders, including antidepressants, anticonvulsants, benzodiazepines, and antipsychotics. Novel approaches to somatization include treatment with cannabinoids, ketamine, opioid antagonists, and peppermint oil. Data on pharmacological management of heterogeneous somatoform disorders ranges from sparse to substantial. A rehabilitative intervention model consisting of pharmacological and nonpharmacological modalities with simultaneous treatment of psychiatric comorbidities is recommended.